Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SNR3C2
The experimentally established mechanism targets of Nimodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 9/20 | 0.82 |
| ▸ | CACNA1F known ✓ | O60840 | 8/20 | 0.82 |
| ▸ | CACNA1D known ✓ | Q01668 | 8/20 | 0.82 |
| ▸ | CACNA1S known ✓ | Q13698 | 8/20 | 0.82 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimodipine SCHEMBL29382758 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL34041 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL30425942 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL8531069 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| (S)-Nimodipine SCHEMBL34042 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL27757251 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL27608151 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL142534 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL28487234 | 0.97 | MEN1 (0.94) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL26110731 | 0.97 | MEN1 (0.94) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108310234-A | A kind of pharmaceutical composition for treating cognition dysfunction and preparation method thereof, preparation and application | 昆药集团股份有限公司 | 2018-07-24 | — | — | CN | disclosed |
| CN-106138135-A | Medicine for treatment of vascular cognitive disorder and preparation method thereof | 四川省中医药科学院 | 2016-11-23 | — | — | CN | disclosed |
| CN-101398414-B | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST DEPT OF SHANGHAI POLICE STATION | 2011-07-20 | — | — | CN | disclosed |
| CN-101398414-A | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST GENERAL UNIT O (CN) | 2009-04-01 | — | — | CN | disclosed |
| US-20090030071-A1 | Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol | DEY PHARMA, L.P. (F/K/A DEY, L.P.) | 2009-01-29 | — | — | US | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| WO-2007012064-A2 | PREVENTION AND TREATMENT OF HEARING DISORDERS | CYPRESS BIOSCIENCE, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-5478848-A | Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine | BAYER CORPORATION (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1990011769-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELLTECH LIMITED (GB) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030071-A1 | Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol | ADRB3, ADRB1, ADRB2 | CACNA1C 732/4885CACNA1F 466/4885CACNA1D 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.